ACA
YMAB

Avoro Capital Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Avoro Capital Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-310,000
Closed -$6.3M – 37
2018
Q4 		$6.3M Hold
310,000
– – 0.38% 28
2018
Q3 		$8.23M Buy
+310,000
New +$7.88M 0.38% 33

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Avoro Capital Advisors's YMAB Position: Q1 2019 in Review

Avoro Capital Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2019, closing a stake of 310,000 shares — an estimated $6.3M sold.

Avoro Capital Advisors first reported a position in YMAB in Q3 2018 and held it in 2 quarters. The position peaked at $8.23M in Q3 2018. 45 funds tracked by Wall St. Rank hold YMAB as of Q1 2019.

  • Avoro Capital Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Avoro Capital Advisors sold 310,000 Y-mAbs Therapeutics shares in Q1 2019, an estimated $6.3M.
  • Avoro Capital Advisors first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 2 quarters.
  • Avoro Capital Advisors's Y-mAbs Therapeutics position peaked at $8.23M in Q3 2018.
  • 45 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2019.

Based on Avoro Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.